In very elderly patients, less aggressive skin cancers on the face might not always need to be treated, a new study suggests.

News

By Ben Hirschler

MADRID (Reuters) - Bristol-Myers Squibb’s immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.

Read More

By Marilynn Larkin

NEW YORK (Reuters Health) – People who carry a BsmI single-nucleotide polymorphism (SNP) are twice as likely to develop nonmelanoma skin cancer (NMSC) as their peers with similar known risk factors, such as older age, male sex, and light eye and skin color, researchers say.

Read More

By Will Boggs MD

NEW YORK (Reuters Health) - Men who use phosphodiesterase type 5 (PDE5) inhibitors have a slightly increased risk of developing melanoma and basal cell carcinoma, according to a new meta-analysis.

Read More

By Marilynn Larkin

NEW YORK (Reuters Health) - Contrary to current guidelines, early melanoma patients under age 40 may be more suitable for sentinel lymph node biopsy (SLNB) than those over age 65, researchers in Pennsylvania suggest.

Read More

Research in Review

A combination of immunotherapy treatments improves survival and lowers the risk of life-threatening events for patients with late-stage melanoma compared with targeted therapy, according to a new JAMA Oncology report.

-----

Related Content

Read More

Specialized surveillance may be more cost effective and lead to fewer invasive procedures compared with standard care for patients with a high risk of melanoma, according to a study published in the Journal of Clinical Oncology.   

Read More

Culturing T cells in N-acetyle cysteine (NAC) before they are infused as immunotherapy may improve effectiveness and outcomes in patients with melanoma, according to findings reported in Cancer Research.

Read More

Adaptive immune signatures in tumor biopsy samples obtained early during the course of treatment may be used to predict patient response to melanoma immunotherapy, according to a study published in Cancer Discovery.

Read More

Subscribe to Skin Cancer